Evidence map›Paper›PMID 7977648›Full record

ArticleThe American journal of pathology1994

Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p.

J Reifenberger, G Reifenberger, L Liu, C D James, W Wechsler, V P Collins

Open access · greenAbstract read
In one paragraph

Article in The American journal of pathology, 1994. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 170 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
170citing papers in PubMed, 4 pooled it
5.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

170 citing papers in PubMed, 4 syntheses or guidelines pooled it, 606 citations in OpenAlex.

  1. Guideline
  2. Guideline
  3. Pooled it
  4. Guideline
  5. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2014
    Trial
  6. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2013
    Trial
  7. Trial
  8. Trial
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Observational
  18. Review
  19. Article
  20. Article

110 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

J ReifenbergerDepartment of Pathology, Sahlgrenska Hospital, Gothenburg, Sweden.
G Reifenberger
L Liu
C D James
W Wechsler
V P Collins
Sahlgrenska University Hospital · SE

Funding

GENETIC ALTERATIONS IN CNS TUMOR DEVELOPMENTR01CA055728 · NCI · MAYO CLINIC COLL OF MEDICINE, ROCHESTER · PI JAMES, CHARLES DAVID · 1991 to 1999
–
NCI NIH HHS CA-55728
6 · The paper itself

Abstract

The molecular genetic alterations of oligodendroglial tumors and mixed gliomas of the central nervous system were studied in a series of 37 cases (8 oligodendrogliomas, 13 anaplastic oligodendrogliomas, 8 oligoastrocytomas, and 8 anaplastic oligoastrocytomas). A total of 180 polymorphic loci and 5 nonpolymorphic gene loci, distributed over all chromosomes, were examined by restriction fragment length polymorphism analysis. Loss of heterozygosity was most frequently observed for loci on 19q with a commonly deleted region at 19q13.2-q13.4 distal to the CYP2a gene and proximal to the D19S22 locus. The incidence of allelic loss on 19q was particularly high (81%) in oligodendroglial tumors and equal to 31% in mixed gliomas. More than 75% of the tumors with allelic deletions on 19q also showed loss of heterozygosity for loci on 1p with one tumor showing only loss of alleles distal to the NGFB gene (1p13-pter). Seven (19%) tumors had lost alleles from 17p with the deleted region including the TP53 tumor suppressor gene in all cases. Sequencing of the TP53 transcripts from exons 2 to 10, however, did not reveal mutations of the remaining allele in any of these tumors. Anaplastic oligodendrogliomas and anaplastic oligoastrocytomas demonstrated an increased incidence of additional allelic losses involving most frequently chromosomes 9p and 10. Gene amplification was detected in two anaplastic tumors, affecting the epidermal growth factor receptor gene in both cases, with additional amplification of the renin gene at 1q32 in one of these cases. In total our results indicate both differences and similarities between the molecular genetic alterations in tumors with oligodendroglial and astrocytic differentiation. The loss of genetic information from 19q and 1p as well as the rarity of TP53 mutations in oligodendroglial tumors suggests that the early events in their oncogenesis are distinct from those associated with astrocytic tumors. However, similarities are indicated by the allelic losses on 9p and 10 in the anaplastic tumors, suggesting the utilization of common pathways of progression.

Indexed as

Chromosome DeletionChromosomes, Human, Pair 1Chromosomes, Human, Pair 19AdolescentAdultAgedAllelesBase SequenceBrain NeoplasmsChildChild, PreschoolDNA, NeoplasmDNA PrimersFemaleHeterozygoteHumansDNA, NeoplasmDNA PrimersTumor Suppressor Protein p53

Identifiers

PMID7977648
PMCPMC1887413
OpenAlexW1878193927

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.